SCOTTSDALE, Ariz., Dec. 4 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for pharma and biotech companies with a stake in the market for T2 diabetes therapies.
In this report, entitled "MedPredict Thought Leader Insight & Analysis: T2 Diabetes," physician experts discuss the interplay between diabetes and cardiovascular disease.
"Recent changes to the American Diabetes Association guidelines
highlight the diabetic's increased risk for coronary artery disease (CAD),"
according to MedPredict's President Jeff Berk. "In light of these
guidelines, our Panel provides insight into unmet needs and the
endocrinologist's emerging therapeutic management strategies for diabetes,
CAD, metabolic syndrome and nonalcoholic steatohepatitis (NASH)."
-- Incretins will dominate new launches for HbA1c lowering drugs for the
next few years. The Panel discusses the significance of targeting
DPP4, DPP8 and DPP9, and compares this class with GLP-1 agonists.
Strengths and weaknesses of new monotherapies and combination
approaches are discussed.
-- These new orals and parenterals will put pressure on established
products, including metformin, sulfonylureas and TZDs. The Panel
offers insight into how each fits into the diabetes / CAD paradigm.
-- The Panel describes why Exubera has failed commercially, and
benchmarks next-generation insulins.
-- While still very early in development, the Panel shared key insights
about the future for inhibition of SGLT.
Key products mentioned in this report: metformin, Januvia/Janumet
(sitagliptin; Merck), Byetta (exenatide; Lilly/Amylin), exenatide LAR
(Lilly/Amylin/Alkermes), Symlin (Amylin), pramlintide + leptin
(Amylin/Amgen), Galvus (vildagliptin; N
Copyright©2007 PR Newswire.
All rights reserved